Patient description: A 5 months old male brought to the pediatrics surgery clinic with the complaint of empty scrotum at the right side. The baby boy is a first child who was born at the age of 38 weeks with NVD from a healthy mother. The mother had a normal pregnancy with no complication. The baby boy weighted 3200 gr with the height of 50 cm. He is breast feeding and now weighted as 6.5 kg with the height of 62 cm. He has no developmental delay in the physical assessment. There is a palpable testis is the left scrotum with non-palpable testis in the right scrotum. The penis is normal in shape and size and he is not circumcised. The diagnostic laparoscopy showed an abdominal undescended testis.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Community Acquired Bacterial Pneumonia Male or female 18 years of age or older 2. Evidence of acute onset of CABP with 2 or more of the following symptoms (new or worsening) Cough Production of purulent sputum consistent with bacterial infection Difficulty breathing Chest pain due to pneumonia AND have at least 2 of the following findings Fever (oral temperature >38.0°C) Hypothermia (oral temperature <35.0°C) Tachycardia (heart rate >100 beats/min) Tachypnea (respiratory rate >18 breaths/min) AND have at least 1 of the following findings Hypoxemia (oxygen saturation <90% or PaO2 < 60 mmHg) on room air or with subject's baseline (pre-CABP under study) supplemental oxygen  A medical history of significant hypersensitivity or allergic reaction to antibiotics of the quinolone or oxazolidinone class or study drug excipients according to the investigator 2. Any infection expected to require other systemic antibiotics in addition to study drug 3. Receipt of systemic antibiotic therapy in the 7 days before enrollment unless 1 of the following is documented Received at least 48 hours of antibiotic therapy for CABP and clinic notes document treatment failure (i.e., not by patient history or pulmonary imaging alone) with new or worsening symptoms while on pre-study therapy Received 1 dose of a single, potentially effective, short-acting antibacterial drug or drug regimen for CABP within 24 hours before enrollment (limited to 25% of enrolled patients) 4. Respiratory infection confirmed or suspected to be secondary to hospital-acquired or ventilator-associated pneumonia OR requires treatment in an intensive care setting, OR requires mechanical ventilation 5. Current or suspected diagnosis of viral, fungal, or aspiration pneumonia, noninfectious causes of pulmonary infiltrates, lung cancer, cystic fibrosis, tuberculosis, empyema (not including sterile parapneumonic effusions) 6. Known anatomical or pathological bronchial obstruction OR history of bronchiectasis OR GOLD Stage 4 COPD OR history of post obstructive pneumonia 7. Severely compromised immune system 8. Known history of Child-Pugh Class B or C liver disease 9. History of post-antibiotic colitis within last 3 months 10. Other exclusions those described in the safety label for drugs in the quinolone and/or oxazolidinone classes such as QT prolongation, proarrhythmic conditions, concomitant use of drugs known to cause QT prolongation, peripheral neuropathy, tendon disorders, history of myasthenia gravis, liver disease, severe renal disease, seizures and concomitant use of MAO A or B inhibitor agents and adrenergic serotonergic agents